Aspira Women's Health, Inc. to Add National Comprehensive Cancer Network Management Recommendations to Its Proprietary Aspira GenetiXTM Clinical Report
February 12, 2021
February 12, 2021
AUSTIN, Texas, Feb. 12 (TNSRes) -- The National Comprehensive Cancer Network issued the following news release on Feb. 11, 2021:
Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced they will incorporate management recommendations from NCCN Guidelines(R) into our Aspira GenetiX Clincal reports. Aspira GenetiX is our personalized hereditary cancer genetic risk testing service that offers panels specifically curated to detect pathoge . . .
Aspira Women's Health, Inc. (Nasdaq: AWH), a bioanalytical-based women's health company, today announced they will incorporate management recommendations from NCCN Guidelines(R) into our Aspira GenetiX Clincal reports. Aspira GenetiX is our personalized hereditary cancer genetic risk testing service that offers panels specifically curated to detect pathoge . . .